| 引用本文:袁炜婷1，2，孙飞龙1，2，赵高娃2，3，王钦富3，刘海娘3，程栋3，曹雅兰1，向姝婷1，王钰4，张斯琪4，肖何柳3，于勤1，2.养心氏对慢性心力衰竭患者血流动力学及氧化应激指标的影响[J].世界中医药,2019,(04):. |
|
| 养心氏对慢性心力衰竭患者血流动力学及氧化应激指标的影响 |
| Effect of Yangxinshi on Hemodynamics and Oxidative Stress in Patients with Chronic Heart Failure |
| 投稿时间：2019-01-30 |
| DOI：10.3969/j.issn.1673-7202.2019.04.027 |
| 中文关键词: 养心氏 慢性心力衰竭 血流动力学 氧化应激 过氧化氢酶 琥珀酸脱氢酶 谷胱甘肽-过氧化物酶 丙二醛 超氧化物歧化酶 |
| English Keywords:Yangxinshi Chronic heart failure Hemodynamics Oxidative stress Catalase(CAT) Succinic dehydrogenase(SDH) Glutathione peroxidase(GsH-Px) Malonaldehyde(MDA) Superoxide dismutase(SOD) |
| 基金项目:国家自然科学基金项目(81770405);辽宁省自然科学基金项目（201602033） |
|
| 摘要点击次数: 763 |
| 全文下载次数: 565 |
| 中文摘要: |
| 目的：探讨优化药物治疗的基础上，养心氏对慢性心力衰竭患者血流动力学及氧化应激的影响。方法：选取2017年10月至2018年4月间大连大学附属中山医院心内科因慢性心力衰竭急性加重住院，病情稳定2～4周并知情同意参与本研究的患者80例作为研究对象，随机分为对照组及养心氏组，每组30人，曲美他嗪组及养心氏+曲美他嗪组，每组10人。分别应用无创心脏血流动力检测仪检测左室射血分数(Left Ventricular Ejection Fraction,LVEF）及每搏输出量（Stroke Volume，SV），采用酶联免疫吸附试验(Enzyme-linked Immunosorbent Assay,ELISA)法检测过氧化氢酶(Catalase,CAT)、琥珀酸脱氢酶(Succinic Dehydrogenase,SDH)、谷胱甘肽-过氧化物酶(Glutathione Peroxidase,GsH-Px)、丙二醛(Malonaldehyde，MDA)、超氧化物歧化酶(Superoxide Dismutase,SOD)等氧化应激指标的变化。采用SPSS 24统计软件进行数据处理，采用t检验对组内基线及6个月随访的数据进行分析；采用One-way ANOVA分析对6个月随访指标进行组间比较。该研究方案已经过Clinical trail注册（ID:NCT03333499）。结果：6个月随访时，养心氏组、曲美他嗪组、养心氏+曲美他嗪组的LVEF值、SV值均较同组基线时显著提高(P<0.05)，6个月随访时3组分别与对照组比较，LVEF值、SV值均显著升高(P<0.05)。4组的CAT、SDH、GsH-Px、SOD均较同组基线时显著升高(P<0.05)；MDA较同组基线时显著降低（P<0.05)。6个月随访时养心氏组、曲美他嗪组、养心氏+曲美他嗪组分别与对照组CAT、SDH等氧化应激相关因子比较均有显著改善（P<0.05)；且两两比较无统计学意义。结论:在优化药物治疗基础上，养心氏可以显著改善慢性心力衰竭患者的血流动力学，有效改善心功能，降低机体氧化应激损伤。 |
| English Summary: |
| To explore the effects of Yangxinshi on hemodynamics and oxidative stress in patients with chronic heart failure based on optimized drug therapy.Methods:Eighty patients of acute heart failure admitted to the Department of Cardiology，Zhongshan Hospital Affiliated to Dalian University from October 2017 to April 2018 with stable condition for 2 to 4 weeks and informed consent were enrolled in this study.They were randomly divided into the control group，the Yangxinshi group，with 30 in each group，the Trimetazidine group and the Yangxinshi+ Trimetazidine group，with 10 in each group.The left ventricular ejection fraction(LVEF）and stroke volume(SV）were measured by non-invasive cardiac blood flow tester.Changes in oxidative stress indicators such as catalase(CAT)，succinate dehydrogenase(SDH)，glutathione-peroxidase(GsH-Px)，malondialdehyde(MDA)，and superoxide dismutase(SOD）were measured by enzyme-linked immune sorbent assay(ELISA).SPSS 24 software was used to process data.T test was used to analyze the data at baseline and 6 months' follow-up in the groups.One-way ANOVA analysis was used to compare the indicators of 6 months' follow-up.The project has been registered in Clinical trail(Registration number：NCT03333499）and examined by the Ethics Committee of Zhongshan Hospital Affiliated to Dalian University.Results:During 6 months follow-up，the LVEF and SV values of the Yangxinshi group，Trimetazidine group，Yangxinshi and Trimetazidine group were significantly improved compared with the baseline of the same group(P<0.05).The LVEF and SV values of the 3 groups were significantly higher than those of the control group(P<0.05).The CAT，SDH，GsH-Px and SOD of the 4 groups were significantly increased than those of the same group(P<0.05); MDA was significantly decreased than the baseline of the same group(P<0.05).The Yangxinshi group，Trimetazidine group，Yangxinshi and Trimetazidine group were significantly improved in oxidative stress-related factors such as CAT compared with the control group(P<0.05); There was no statistical differences among them.Conclusion:On the basis of optimizing drug treatment，Yangxinshi can improve blood pressure of patients with chronic heart failure，the patient's hemodynamics and the heart function，as well as reduce the body's oxidative stress damage with high safety，which can be applied clinically. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
